Literature DB >> 20805393

Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Thomas P Young1, Neil T Parkin, Eric Stawiski, Tami Pilot-Matias, Roger Trinh, Dale J Kempf, Michael Norton.   

Abstract

Patterns of HIV-1 protease inhibitor (PI) resistance-associated mutations (RAMs) and effects on PI susceptibility associated with the L76V mutation were studied in a large database. Of 20,501 sequences with ≥1 PI RAM, 3.2% contained L76V; L76V was alone in 0.04%. Common partner mutations included M46I, I54V, V82A, I84V, and L90M. L76V was associated with a 2- to 6-fold decrease in susceptibility to lopinavir, darunavir, amprenavir, and indinavir and a 7- to 8-fold increase in susceptibility to atazanavir and saquinavir.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805393      PMCID: PMC2976162          DOI: 10.1128/AAC.00906-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Authors:  Jeannette M Whitcomb; Neil T Parkin; Colombe Chappey; Nicholas S Hellmann; Christos J Petropoulos
Journal:  J Infect Dis       Date:  2003-09-16       Impact factor: 5.226

Review 2.  Update of the drug resistance mutations in HIV-1: December 2009.

Authors:  Victoria A Johnson; Francoise Brun-Vezinet; Bonaventura Clotet; Huldrych F Gunthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2009-12

3.  The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.

Authors:  Elena Knops; Ina Kemper; Eugen Schülter; Herbert Pfister; Rolf Kaiser; Jens Verheyen
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

4.  In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.

Authors:  H Z Bazmi; J L Hammond; S C Cavalcanti; C K Chu; R F Schinazi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.

Authors:  R Ziermann; K Limoli; K Das; E Arnold; C J Petropoulos; N T Parkin
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

Authors:  Monique Nijhuis; Annemarie M J Wensing; Wouter F W Bierman; Dorien de Jong; Ron Kagan; Axel Fun; Christian A J J Jaspers; Karin A M Schurink; Michael A van Agtmael; Charles A B Boucher
Journal:  J Infect Dis       Date:  2009-09-01       Impact factor: 5.226

7.  Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Authors:  Constance Delaugerre; Philippe Flandre; Marie Laure Chaix; Jade Ghosn; François Raffi; Pierre Dellamonica; H Jaeger; D Shürmann; Isabelle Cohen-Codar; Philippe Ngo Van; Michael Norton; Anne-Marie Taburet; Jean-François Delfraissy; Christine Rouzioux
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

8.  3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.

Authors:  B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

9.  Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.

Authors:  Wei Huang; Andrea Gamarnik; Kay Limoli; Christos J Petropoulos; Jeannette M Whitcomb
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors:  M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal:  Antivir Ther       Date:  1999
View more
  22 in total

1.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

Review 2.  2011 update of the drug resistance mutations in HIV-1.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Günthard; Roger Paredes; Deenan Pillay; Robert Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2011-11

3.  Characterizing Protein-Ligand Binding Using Atomistic Simulation and Machine Learning: Application to Drug Resistance in HIV-1 Protease.

Authors:  Troy W Whitfield; Debra A Ragland; Konstantin B Zeldovich; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2020-01-16       Impact factor: 6.006

4.  Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Ravikiran S Yedidi; Rui Zhao; Hironori Hayashi; Kazuya Hasegawa; Tomofumi Nakamura; Cuthbert D Martyr; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 5.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

6.  HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.

Authors:  Moussa Thiam; Halimatou Diop-Ndiaye; Aminata Diaw Diouf; Nicole Vidal; Ousseynou Ndiaye; Ibrahima Ndiaye; Ndeye Fatou Ngom-Gueye; Sada Diallo; Oumy Diop Diongue; Makhtar Camara; Abdoulaye Seck; Souleymane Mboup; Coumba Toure-Kane
Journal:  J Clin Microbiol       Date:  2012-12-12       Impact factor: 5.948

7.  The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.

Authors:  John M Louis; Ying Zhang; Jane M Sayer; Yuan-Fang Wang; Robert W Harrison; Irene T Weber
Journal:  Biochemistry       Date:  2011-05-03       Impact factor: 3.162

8.  2019 update of the drug resistance mutations in HIV-1.

Authors:  Annemarie M Wensing; Vincent Calvez; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Huldrych F Günthard; Roger Paredes; Robert W Shafer; Douglas D Richman
Journal:  Top Antivir Med       Date:  2019-09

9.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting.

Authors:  Almoustapha Issiaka Maiga; Djeneba Bocar Fofana; Mamadou Cisse; Fodié Diallo; Moussa Youssoufa Maiga; Hamar Alassane Traore; Issouf Alassane Maiga; Aliou Sylla; Dionke Fofana; Babafemi Taiwo; Robert Murphy; Christine Katlama; Anatole Tounkara; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  J Antimicrob Chemother       Date:  2012-08-10       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.